about
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadeTrial Watch-Immunostimulation with cytokines in cancer therapyKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentIntramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domainsOxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodiesAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus.Future therapies of wet age-related macular degeneration.Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.Increased Fab thermoresistance via VH-targeted directed evolution.Ligand-targeted theranostic nanomedicines against cancerCharacterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuous scatteringA fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive MalignanciesA Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface TargetsAntibodies to watch in 2016.Antibodies to watch in 2017Chemical biology: How to minimalize antibodies.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi.Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity.Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study.Statistical characterization of therapeutic protein modifications.Single-domain antibodies for biomedical applications.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Secukinumab (AIN-457) for the treatment of Psoriasis.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Identification of regulatory motifs in the CHO genome for stable monoclonal antibody production.Process development of a human recombinant diabody expressed in E. coli: engagement of CD99-induced apoptosis for target therapy in Ewing's sarcoma.Advances in PET Detection of the Antitumor T Cell Response.Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.The Regulatory Function of EosinophilsCardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application scheduleOpportunities for therapeutic antibodies directed at G-protein-coupled receptors.Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC.
P2860
Q26799443-F22B411F-C3AC-4ED0-AAB2-5A7054858C81Q28078725-6E46A0E4-9A42-4655-AFDD-2F5F192F0A7EQ28082880-9C742917-6B35-4C40-897E-D736DC0219BFQ28597266-50B1DADC-47D4-4BA3-A64D-0A4C625698D2Q28821982-AEFDCEF5-D353-428B-8DEE-F3955CA30A19Q30275229-DA2F183B-851B-4D7F-B652-BE1996139926Q33652093-9D34F6A4-5F81-44A4-BC34-84E838D0975CQ35162495-971B7CEF-3073-4AFD-96E6-197AE0FCE908Q35723422-F576B65C-805A-4FD8-A83F-611581374C49Q35748485-CD38B23F-ADED-473A-83D5-72F2BCDF1EBDQ35895637-4272CFA3-371C-4ED8-B8A7-A6FCA58F78A7Q35975965-4117E58B-7637-4058-AC75-4BE3E02F4C6EQ35993123-96F91C55-9DAA-46BD-973E-0428C734BDD4Q36100648-3E9B4068-F993-40B8-ABC4-1953FD3FFE2FQ36240389-5F7002FE-60DC-4F8A-9714-CA79F0DD584CQ36965071-FA97A18B-E7EE-47F7-9AFE-D1CB4C11C0C5Q36987701-E58CA8F2-67CA-4E99-8FF3-1D816294D9C3Q37138505-0425080E-CE23-447A-9B8F-4095B2A65FD4Q37631319-FF96B5BF-189A-4E4F-B7E3-6CF94371952CQ38445478-E62C6585-2503-469B-8384-31D62ACF46DAQ38530254-B1F994E8-B35E-454A-AF3F-51FE9250DCB3Q38612388-A340C180-8F93-4461-AD01-0523B630B260Q38615389-2007F6AA-7BEF-43EA-9D62-1DD23D4F4EADQ38628086-C02CD495-CA82-47DC-951D-EE29CA0104F0Q38628116-2E5E37A4-BD33-441B-AD92-6B23874905B3Q38628712-DDF659D8-EB53-49D1-951F-399224BA7F8DQ38633532-02FDABE3-50CF-4F7F-96FA-D8DA2C41D182Q38662868-17295EDD-9266-4332-AE2E-D7E881578DB7Q38665164-8577A58D-9AC9-49EF-9CE4-5D334170C77FQ38750911-BB9B1D0D-FAD0-4EF5-9E98-E3F01246C289Q38810472-A42AE355-13B8-434F-8093-5FE6CB48420AQ38846891-D075C3A5-4C4F-4B80-BBFC-7E9A817422C3Q38910201-1B1D61D8-A198-4D70-BDA1-A02AF064ACE4Q38979169-6A16837E-C8AA-4D8D-96B9-E315D23FE5E9Q38990422-244FA338-5382-4796-8523-1D9D5ED13C1CQ39344380-158AC97D-2E20-4581-B320-3E25D16E6B1DQ39358414-008C0595-B54B-4AF0-AE2F-34FB94F43DF1Q39433833-48F18276-A807-4D4F-9267-0B405F1350FFQ39731345-0D7C213C-2828-424F-A039-681548841F2EQ40064011-7A8CB6AB-B872-4BF2-BBAF-CBFCEE95E12E
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Antibodies to watch in 2015
@ast
Antibodies to watch in 2015
@en
Antibodies to watch in 2015
@nl
type
label
Antibodies to watch in 2015
@ast
Antibodies to watch in 2015
@en
Antibodies to watch in 2015
@nl
prefLabel
Antibodies to watch in 2015
@ast
Antibodies to watch in 2015
@en
Antibodies to watch in 2015
@nl
P2860
P3181
P1476
Antibodies to watch in 2015
@en
P2860
P3181
P356
10.4161/19420862.2015.988944
P407
P577
2015-01-01T00:00:00Z